Skip to main content

Day: April 7, 2025

Myriad Genetics Names Brian Donnelly as New Chief Commercial Officer

SALT LAKE CITY, April 07, 2025 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, announced today the appointment of Brian Donnelly as chief commercial officer (CCO), effective May 1, 2025. A strategic, results-oriented leader with more than 20 years of experience in healthcare, diagnostics, and medical technology, Donnelly has a proven track record of building and leading high-performing teams, managing multi-billion-dollar P&Ls, and driving growth through innovative go-to-market strategies. “Brian brings a unique combination of strategic vision and operational excellence, combined with a passion for patient-centric solutions and a strong focus on commercial execution,” said Sam Raha, incoming president and CEO of Myriad Genetics. “He will be a critical...

Continue reading

P10 Completes Acquisition of Qualitas Funds, a Leading European Lower-Middle Market Alternative Investment Solutions Provider

DALLAS, April 07, 2025 (GLOBE NEWSWIRE) — P10, Inc. (NYSE: PX) (“P10” or the “Company”), a leading private markets solutions provider, today announced it has completed its previously announced acquisition of Qualitas Equity Funds SGEIC, S.A. (“Qualitas Funds”) for an initial purchase price of $63 million, with the potential for additional earnout consideration. Qualitas Funds is a Madrid-based private equity investing platform that provides fund-of-funds, direct co-investing and NAV financing opportunities in the European lower-middle market to more than 1,300 limited partners across the ultra-high-net-worth (UHNW), family office, and institutional channels. The firm has approximately $1 billion in fee-paying assets under management (FPAUM) and a strong expected growth trajectory. The firm was founded in 2015 by co-founders and...

Continue reading

Prime Drink Group Announces Its Intent to Acquire Relax Downlow, The Latest Brand to Collaborate with Lane Hutson

With this acquisition, Prime is entering the fast-growing relaxation beverage market, which is expected to reach $1.3 billion by 2030, with a projected CAGR of more than 15%1. Lane Hutson, NHL star player, becomes the official ambassador of Relax Downlow. Relax Downlow has just launched its first flavors, Citrus Iced Tea and Tropical Punch, in the largest chain of convenience stores in Quebec and in the upscale hotel sector.MONTREAL, April 07, 2025 (GLOBE NEWSWIRE) — Prime Drink Group Corp. (CSE: PRME) (“Prime” or the “Company”) is pleased to announce that it has entered into a binding letter of intent dated April 3, 2025, to acquire a 70% interest in 9375-4208 Quebec Inc. (the “Target”), a corporation governed by the laws of Quebec (the “Proposed Transaction”). The Target is the owner of Relax Downlow, a brand of recovery functional...

Continue reading

Dundee Precious Metals Annual and Special Meeting of Shareholders to be held May 7, 2025

TORONTO, April 07, 2025 (GLOBE NEWSWIRE) — Dundee Precious Metals Inc. (TSX: DPM) (“DPM” or “the Company”) announces its Annual and Special Meeting of Shareholders will be held on Wednesday, May 7, 2025, at 4 PM EDT via live audio webcast. Materials for the meeting, including a user guide for accessing the virtual meeting, are available on our website at: https://dundeeprecious.com/investors/investor-centre/#AGMMaterials. Details of the Annual and Special Meeting of Shareholders, including a link to the audio webcast, are as follows:Webcast date and time Wednesday, May 7, 20254 PM EDTWebcast link https://meetnow.global/MXDGNRSReplay Archive will be available on www.dundeeprecious.comMeeting materials Available on www.dundeeprecious.com under Investor Centre   About Dundee Precious Metals Inc. Dundee Precious...

Continue reading

Form 8.3 – [ADVANCED MEDICAL SOLUTIONS GROUP PLC – 04 04 2025] – (CGWL)

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree ADVANCED MEDICAL SOLUTIONS GROUP PLC(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e)   Date...

Continue reading

Correction: Form 8.3 – Octopus Investments – Advanced Medical Solutions Group plc

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)        Full name of discloser: OCTOPUS INVESTMENTS LTD(b)        Owner or controller of interests and short positions disclosed, if different from 1(a):         The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.  (c)        Name of offeror/offeree in relation to whose relevant securities this form relates:         Use a separate form for each offeror/offeree Advanced Medical Solutions Group plc(d)        If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:  (e)        Date position...

Continue reading

Correction: Form 8.3 – Octopus Investments – Advanced Medical Solutions Group plc

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)        Full name of discloser: OCTOPUS INVESTMENTS LTD(b)        Owner or controller of interests and short positions disclosed, if different from 1(a):         The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.  (c)        Name of offeror/offeree in relation to whose relevant securities this form relates:         Use a separate form for each offeror/offeree Advanced Medical Solutions Group plc(d)        If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:  (e)        Date position...

Continue reading

Correction: Form 8.3 – Octopus Investments – Advanced Medical Solutions Group plc

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)        Full name of discloser: OCTOPUS INVESTMENTS LTD(b)        Owner or controller of interests and short positions disclosed, if different from 1(a):         The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.  (c)        Name of offeror/offeree in relation to whose relevant securities this form relates:         Use a separate form for each offeror/offeree Advanced Medical Solutions Group plc(d)        If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:  (e)        Date position...

Continue reading

Correction: Form 8.3 – Octopus Investments – Advanced Medical Solutions Group plc

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)        Full name of discloser: OCTOPUS INVESTMENTS LTD(b)        Owner or controller of interests and short positions disclosed, if different from 1(a):         The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.  (c)        Name of offeror/offeree in relation to whose relevant securities this form relates:         Use a separate form for each offeror/offeree Advanced Medical Solutions Group plc(d)        If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:  (e)        Date position...

Continue reading

Correction: Form 8.3 – Octopus Investments – Advanced Medical Solutions Group plc

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)        Full name of discloser: OCTOPUS INVESTMENTS LTD(b)        Owner or controller of interests and short positions disclosed, if different from 1(a):         The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.  (c)        Name of offeror/offeree in relation to whose relevant securities this form relates:         Use a separate form for each offeror/offeree Advanced Medical Solutions Group plc(d)        If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:  (e)        Date position...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.